登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>HLA-A*02:01 & B2M & NY-ESO-1 >HL1-H52E8

Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein (MALS & SPR verified)

更有Streptavidin Protein-PESTN-NP117STN-NP119)快速支持您想要的MHC Tetramer组装!

分子别名(Synonym)

HLA-A*02:01 & B2M & NY-ESO-1

表达区间及表达系统(Source)

Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein (HL1-H52E8) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & SLLMWITQC peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769 (B2M) & SLLMWITQC).

Predicted N-terminus: Gly 25 & Ser

蛋白结构(Molecular Characterization)

Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein is assembled by biotinylated monomer (HL1-H82E6) and streptavidin.

Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein is produced by co-expression of HLA and B2M loaded with NY-ESO-1 peptide. Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Complex Protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 36.3 kDa, 13.8 kDa and 13.3 kDa. The protein migrates as 43-47 kDa, 15 kDa and 14 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

HLA-A*02:01 & B2M & NY-ESO-1 SDS-PAGE

Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS

HLA-A*02:01 & B2M & NY-ESO-1 SEC-MALS

The purity of Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein (Cat. No. HL1-H52E8) is more than 90% and the molecular weight of this protein is around 260-290 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

HLA-A*02:01 & B2M & NY-ESO-1 ELISA

Immobilized Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein (Cat. No. HL1-H52E8) at 5 μg/mL (100 μL/well) can bind Anti-NY-ESO-1 Antibody, Human IgG1 with a linear range of 0.001-0.313 μg/mL (QC tested).

Protocol

HLA-A*02:01 & B2M & NY-ESO-1 ELISA

Immobilized Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein (Cat. No. HL1-H52E8) at 1 μg/mL (100 μL/well) can bind Anti-B2M Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (Routinely tested).

Protocol

 

活性(Bioactivity)-SPR

HLA-A*02:01 & B2M & NY-ESO-1 SPR

Anti-NY-ESO-1 antibody captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein (Cat. No. HL1-H52E8) with an affinity constant of 1.35 nM as determined in a SPR assay (Biacore 8K) (QC tested).

Protocol

HLA-A*02:01 & B2M & NY-ESO-1 SPR

NY-ESO-1 TCR captured on Protein A Chip can bind Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (Cat. No. HL1-H52E7) with an affinity constant of 15.7 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

 

背景(Background)

NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. The Human HLA-A*0201 NY-ESO-1 (SLLMWITQC) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M and SLLMWITQC peptide of the NY-ESO-1.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定